All Articles

Updated overall survival results from the phase 3 MONALEESA-7 trial show that in a 4-year extended follow-up study of pre- and perimenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer, ribociclib plus endocrine therapy exhibited a clinically relevant overall survival benefit.

BYLieve study results show that alpelisib combined with fulvestrant demonstrates clinically meaningful efficacy and manageable toxicity in patients with hormone receptor–positive, HER2-negative, PIK3CA mutation–positive advanced breast cancer.

While radiation therapy is not currently used in combination with CDK4/6 inhibitors in clinical trial protocols, findings from this study support future consideration of this approach in clinical studies.

In this broad study of a diverse population, adverse events associated with the combination of ribociclib plus letrozole were manageable and consistent with previous phase 3 trials of the same combination, and adverse events of special interest markedly decreased over time.

While showing comparable efficacy, the 3 approved CDK4/6 inhibitors differ in safety and tolerability profiles.

Adopting a maintenance program of everolimus combined with aromatase inhibitors, outcomes were not improved in patients with metastatic breast cancer who were deemed possible candidates for first-line chemotherapy.

Recognition of the common use of chemotherapy and its potential negative impact on quality of life during the final month of life of patients with metastatic breast cancer is essential to efforts to mitigate this practice.

Results of a second interim analysis demonstrate real-world outcomes of treatment with ribociclib, a selective CDK4/6 inhibitor in combination with endocrine therapy.

The majority of patients with metastatic breast cancer receiving treatment with CDK4/6 inhibitors had progression-free survival, behaving similarly when used as first-line therapy or after adjuvant hormonal therapy.